Author

Maëlle Ralu

InsermORCID 0000-0002-3064-1728Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Organism:mouse· 1

Frequent Co-Authors

Francesco Saverio TedescoiD· 2 shared Mario AmendolaiD· 2 shared Alexandre Montanede· 1 shared Anne De CianiD· 1 shared Babette Beher· 1 shared Delphine LeclerciD· 1 shared Emilie Ouanounou· 1 shared Fatima Amor· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Francesco Saverio TedescoORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cancer BiologyMolecular TherapyPeer-reviewedJul 30, 2026

A combinatorial EVs-miRNA signature mediates the anti-tumoral activity of NFAT3-regulated extracellular vesicles in aggressive cancers.

Guenole Tossou, Nadia Ourari, Maëlle Ralu…·Sébastien Jauliac

The paper identifies a combinatorial miRNA signature in EVs regulated by NFAT3 that suppresses tumor aggressiveness in TNBC and pancreatic cancer models.

DOI 10.1016/j.ymthe.2026.07.052

humanbulk RNA-seq

Molecular BiologybioRxivPreprintJul 29, 2026

A Single Lipid Nanoparticle Formulation Enables Delivery of Diverse RNA Therapeutics to Human Muscle Models of Duchenne Muscular Dystrophy

Paola Galbiati, Delphine Leclerc, Margaux Mombled…·Mario Amendola

DOI 10.64898/2026.07.29.741396

humanCRISPR screen

Molecular BiologybioRxivPreprintApr 18, 2023

CRISPR-Cas9 mediated endogenous utrophin upregulation improves Duchenne Muscular Dystrophy

Simon Guiraud, Sumitava Dastidar, Fetta Mazed…·Mario Amendola

This study uses CRISPR-Cas9 to disrupt miR binding sites and upregulate utrophin in DMD models, showing functional improvements and therapeutic potential.

DOI 10.1101/2023.04.18.536394

humanmouse